Format

Send to

Choose Destination
Blood Adv. 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Author information

1
Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Denver, CO.
2
SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA.
3
Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
4
Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
5
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
6
Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
7
James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester, Rochester, NY.
8
Division of Hematology and Oncology, University of Michigan Cancer Center, Dexter, MI.
9
Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY.
10
Department of Medicine, Washington University School of Medicine, St. Louis, MO.
11
Wilmot Cancer Institute, University of Rochester, Rochester, NY; and.
12
Section of Hematology/Oncology, University of Chicago, Chicago, IL.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center